Skip to main content

Table 2 Metabolic, morphological and pathological measurements at M1, Pre-op and on the surgical specimen. Student tests were used to compare metabolic, morphological data and Ki-67 data in mR and mNR. Fisher’s exact tests were used for pathological data

From: Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response

  

mR (5 pts)

mNR (6 pts)

p values

M0

SUVmax (g/mL)

5.4 ± 1.4

4.7 ± 1.5

0.41

Clinical size (mm)

41 ± 11.4

52.5 ± 8.8

0.105

US size (mm)

26.4 ± 4.7

40.3 ± 11.6

0.03

MRI size (mm)

26 ± 3.7

44.7 ± 8.3

0.0016

Ki-67 (%)

10.6 ± 4.4

14 ± 11.1

0.51

M1

SUVmax (g/mL)

2.6 ± 1.1

3.9 ± 1.4

0.00017

Clinical size (mm)

42.5 ± 11.9

51.7 ± 7.5

0.23

US size (mm)

22.6 ± 6.3

34.2 ± 2.4

0.01

MRI size (mm)

20.8 ± 4.2

39.7 ± 4.8

7.1 E-5

Ki-67 (%)

3.6 ± 1.9

8.2 ± 8

0.23

Pre-op

SUVmax (g/mL)

2 ± 1.3

3.3 ± 1.4

0.018

Clinical size (mm)

32 ± 12.5

47.5 ± 10.4

0.06

US size (mm)

18.2 ± 7.3

31.3 ± 9.5

0.041

MRI size (mm)

17.4 ± 6.7

35.8 ± 7.7

0.002

BCS rate

Number of patients

2

2

1

Surgical specimen

Ki 67 (%)

8.6 ± 9.8

12.3 ± 7.9

0.41

Sataloff (TA + TB vs TC + TD) (n)

1 vs 4

0 vs 6

1

 

PEPI score (I + II vs III) (n)

4 vs 1

2 vs 4

0.24